%0 Journal Article %1 Schneider.2008 %A Schneider, B. P. %A Wang, M. %A Radovich, M. %A Sledge, G. W. %A Badve, S. %A Thor, A. %A Flockhart, D. A. %A Hancock, B. %A Davidson, N. %A Gralow, J. %A Dickler, M. %A Perez, E. A. %A Cobleigh, M. %A Shenkier, T. %A Edgerton, S. %A Miller, K. D. %D 2008 %J J.Clin.Oncol. %K & A Antibodies Antineoplastic Breast Chemotherapy Combined Dna Endothelial Factor Female Genotype Growth Haplotypes Hazards Humans Hypertension Models Monoclonal Neoplasms Nonparametric Nucleotide Paclitaxel Polymorphism Proportional Protocols Rate Receptor-2 Research Retrospective Single Statistics Studies Survival Vascular administration dosage drug genetics methods pathology therapeutic therapy toxicity use %N 28 %P 4672-4678 %T Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 %U PM:18824714 %V 26 %X PURPOSE: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer. PATIENTS AND METHODS: DNA was extracted from tumor blocks of patients from E2100. Three hundred sixty-three samples were available to evaluate associations between genotype and outcome. Genotyping was performed for selected polymorphisms in VEGF and VEGF receptor 2. Testing for associations between each polymorphism and efficacy and toxicity was performed. RESULTS: The VEGF-2578 AA genotype was associated with a superior median overall survival (OS) in the combination arm when compared with the alternate ge

@article{Schneider.2008, abstract = {PURPOSE: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer. PATIENTS AND METHODS: DNA was extracted from tumor blocks of patients from E2100. Three hundred sixty-three samples were available to evaluate associations between genotype and outcome. Genotyping was performed for selected polymorphisms in VEGF and VEGF receptor 2. Testing for associations between each polymorphism and efficacy and toxicity was performed. RESULTS: The VEGF-2578 AA genotype was associated with a superior median overall survival (OS) in the combination arm when compared with the alternate ge}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Schneider, B. P. and Wang, M. and Radovich, M. and Sledge, G. W. and Badve, S. and Thor, A. and Flockhart, D. A. and Hancock, B. and Davidson, N. and Gralow, J. and Dickler, M. and Perez, E. A. and Cobleigh, M. and Shenkier, T. and Edgerton, S. and Miller, K. D.}, biburl = {https://www.bibsonomy.org/bibtex/23674c1605b59b98e071107381fac2b75/kanefendt}, interhash = {4b2e84e97b68b9c94cd37f38e68a0fa8}, intrahash = {3674c1605b59b98e071107381fac2b75}, journal = {J.Clin.Oncol.}, keywords = {& A Antibodies Antineoplastic Breast Chemotherapy Combined Dna Endothelial Factor Female Genotype Growth Haplotypes Hazards Humans Hypertension Models Monoclonal Neoplasms Nonparametric Nucleotide Paclitaxel Polymorphism Proportional Protocols Rate Receptor-2 Research Retrospective Single Statistics Studies Survival Vascular administration dosage drug genetics methods pathology therapeutic therapy toxicity use}, number = 28, pages = {4672-4678}, timestamp = {2010-02-05T11:28:50.000+0100}, title = {Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100}, url = {PM:18824714}, volume = 26, year = 2008 }